IMW 2021 | CAR-T vs CAR-NK for myeloma
Hermann Einsele
• 3 Sep 2021
Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, gives an overview of the pros and cons of chimeric antigen receptor T-cell (CAR-T) therapy in comparison to CAR-natural killer (CAR-NK) cell therapy. CAR-T therapies have shown extensive clinical success in multiple hematological malignancies, whereas there is very limited data on the efficacy of CAR-NK cells. While there has been some successful clinical application of CAR-NK cells in the treatment of lymphoma, the mechanisms of persistence and migration in the tumor tissue remain unclear, meaning that this is currently a severely limited treatment option for myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
